Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumorsCombination continues to demonstrate favorable tolerability and a safety profile consistent with the known profiles of ea ...

产品研发 - 羟乙磺酸达尔西利片Ⅲ期临床试验首次期中分析主要终点达统计学显著性[1] - SHR6390 - Ⅲ - 303研究约150家中心完成，入组超5000例受试者[2] - 羟乙磺酸达尔西利片相关项目累计研发投入约117,847万元[9] 产品情况 - 达尔西利已在国内获批两项适应症[4] - 羟乙磺酸达尔西利片是口服、高效、选择性小分子CDK4/6抑制剂[6] 市场数据 - 同类产品2023年全球销售额合计约为108.64亿美元[9] 未来计划 - 公司已向国家药监局药品审评中心递交上市前沟通交流申请[1]